Akelos

Akelos Inc. secures a Chinese patent for its lead compound, advancing its drug development pipeline. The patent covers a key proprietary molecule in its research portfolio, marking a milestone in intellectual property protection for the biotech firm.

Jan 2025EIN PresswireNews article

Akelos Inc. secures a patent allowance from the Japan Patent Office for its lead compound, a novel non-opioid drug targeting chronic and neuropathic pain. The company focuses on developing and commercializing this anti-hyperalgesic treatment as an alternative to opioid-based solutions. This milestone validates the intellectual property for its core therapeutic candidate in the Japanese market.

Oct 2024EIN PresswireNews article

Akelos Inc. secures a **Phase I/II Fast-Track Small Business Technology Transfer (STTR) grant** from the **National Institute of Neurological Disorders and Stroke (NINDS)**. The funding supports early-stage development of neurological disorder treatments or diagnostics. Akelos specializes in neuroscience innovations, though specific project details remain undisclosed.

Oct 2022newswire.comNews article

Akelos Inc. demonstrates that its lead compound—a non-opioid anti-hyperalgesic drug—meets preclinical safety standards. The drug targets chronic and neuropathic pain, addressing unmet needs in pain management without relying on opioids. Researchers validate the compound’s safety profile in early-stage testing, advancing its potential for clinical trials.

Mar 2021newswire.comNews article